Imunon Inc (IMNN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.58+1.28%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · IMNN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 20.8% |
| Our one-year growth estimate | diamond | 0.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 20.8 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
IMNN — CFO transition
Dated 2026-06-30
interim Chief Financial Officer — Jeffrey Church: Mr. Church retired from his position as interim Chief Financial Officer and was succeeded by Josh Blacher.
Why it matters: A strong cash position helps fund clinical trials and lowers risk for shareholders.
Supportive ifCash and cash equivalents are more than $10 million after the recent financing.
Worry ifCash and cash equivalents fall below $6 million, raising concerns about funding for trials.
Why it matters: New capital allocation can show confidence in growth and stability. It may help future projects.
Supportive ifThere is news of new financing or investment in growth plans.
Worry ifNo new news about how the company will use its money or delays in plans.
Why it matters: Good results would build trust in how well IMNN-001 works and its safety.
Supportive ifNew data shows deeper antitumor response and higher rates of ctDNA clearance in the MRD study.
Worry ifResults show no better antitumor response or ctDNA clearance than the control group.
Why it matters: The capital raise is meant to support the OVATION 3 Study and improve cash flow.
Watch forFinancial results show less cash burn and better cash flow.
Also watch forFinancial results show continued high cash burn and negative cash flow.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$186 on $10,000 · ±1.9% | How much price usually moves either way. |
| Bad day | $548 loss on $10,000 · 5.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,405 loss on $10,000 · 74.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: This event may give clues about IMNN-001 and the company's future. Good feedback could improve investor feelings.
Watch forDoctors say good things about how well IMNN-001 works and its safety.
Also watch forNegative feedback or lack of new insights from the R&D Day.
Why it matters: Good cash flow management is key for keeping operations running and funding trials.
Worry ifManagement says there is a big drop in losses or positive cash flow.
Less concerning ifIf losses grow or cash flow stays negative, it shows financial trouble.
Why it matters: Better cash flow and lower losses are key for the company's financial health.
Supportive ifOperating losses drop below $4 million in the next quarter.
Worry ifOperating losses stay above $4 million in the next quarter.
Why it matters: Stable leadership helps carry out the company's plans and keeps investor trust.
Watch forNew leaders make the executive team more stable.
Also watch forMore changes in leaders create uncertainty in the management team.
Why it matters: This deal could bring in money. It may show that investors trust Imunon.
Supportive ifA press release detailing the terms and expected benefits of the agreement.
Worry ifNo further details or negative news about the agreement emerge.
Why it matters: Better cash flow is important for the company's finances. It shows better expense management.
Supportive ifCash flow from operations turns positive for the next quarter.
Worry ifCash flow from operations remains negative or worsens in the next quarter.
Why it matters: New survival data could show IMNN-001 works well and affect investor trust.
Supportive ifNew overall survival data shows better results than the last median of 14.7 months.
Worry ifNew data shows no better overall survival than the past results.
Why it matters: Negative operating income means there are cash flow issues.
Worry ifQ2 operating income is still negative, worse than -$4.3 million.
Less concerning ifIf Q2 operating income turns positive or gets much better.
Why it matters: New responsibilities could change cash flow and how well the company runs.
Worry ifManagement says it has less money to pay or better cash flow.
Less concerning ifManagement talks about new money duties. They may also mention lower cash flow.
Why it matters: Completing enrollment is key for advancing IMNN-001 towards potential approval. It shows strong interest and confidence in the treatment.
Supportive ifEnrollment in the Phase 3 OVATION 3 trial finishes early. It is faster than expected.
Worry ifEnrollment stalls or falls behind the planned timeline.
Why it matters: Good results would boost confidence in IMNN-001's effectiveness. It supports its use in advanced ovarian cancer.
Supportive ifNew data shows better rates of tumor DNA clearance. There is no sign of disease in patients treated with IMNN-001.
Worry ifData shows no better tumor response or clearance rates compared to control.
Why it matters: Good cost management is important for keeping operations running. It helps advance clinical trials.
Worry ifOperating costs go down or stay the same while helping trial work.
Less concerning ifOperating costs rise a lot with no trial progress.
Why it matters: This financing is key for the Phase 3 trial. It could impact the company's financial health.
Watch forThe financing speeds up enrollment in the OVATION 3 trial. It also helps financial stability.
Also watch forThe funding does not lead to more enrollments or financial growth.